title: Dexamethasone reduces energy expenditure and increases susceptibility to diet-induced obesity in mice.
abstract: OBJECTIVE
  To investigate how long-term treatment with dexamethasone affects energy expenditure and adiposity in mice and whether this is influenced by feeding on a high-fat diet (HFD).
  
  
  METHODS
  Mice were placed on a HFD for 2 weeks and started on dexamethasone at 5 mg/kg every other day during the next 7 weeks.
  
  
  RESULTS
  Treatment with dexamethasone increased body fat, an effect that was more pronounced in the animals kept on HFD; dexamethasone treatment also worsened liver steatosis caused by the HFD. At the same time, treatment with dexamethasone lowered the respiratory quotient in chow-fed animals and slowed nightly metabolic rate in the animals kept on HFD. In addition, the acute VO2 acceleration in response to β3 adrenergic-stimulation was significantly limited in the dexamethasone-treated animals, as a result of marked decrease in UCP-1 mRNA observed in the brown adipose tissue of these animals.
  
  
  CONCLUSIONS
  Long-term treatment with dexamethasone in a mouse model of diet-induced obesity decreases brown adipose tissue thermogenesis and exaggerates adiposity and liver steatosis. © 2013 American Institute of Chemical Engineers AIChE J, 2013.
authors: Division of Endocrinology Diabetes and Metabolism, University of Miami Miller School of Medicine, Miami, Florida, USA.
authors: Raffaella
authors: R
authors: Poggioli
authors: Cintia B
authors: CB
authors: Ueta
authors: Rafael Arrojo E
authors: RA
authors: Drigo
authors: Melany
authors: M
authors: Castillo
authors: Tatiana L
authors: TL
authors: Fonseca
authors: Antonio C
authors: AC
authors: Bianco
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects* / Q000378:metabolism; D002001:Adipose Tissue, Brown / Q000378:metabolism; D050154:Adiposity / Q000187:drug effects; D000818:Animals; D001481:Basal Metabolism / Q000187:drug effects; D003907:Dexamethasone / Q000009:adverse effects* / Q000494:pharmacology; D059305:Diet, High-Fat / Q000009:adverse effects*; D004041:Dietary Fats / Q000008:administration & dosage; D004195:Disease Models, Animal; D004734:Energy Metabolism / Q000187:drug effects*; D005234:Fatty Liver / Q000209:etiology; D005938:Glucocorticoids / Q000009:adverse effects* / Q000494:pharmacology; D007473:Ion Channels / Q000235:genetics / Q000378:metabolism; D008099:Liver / Q000187:drug effects; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D024101:Mitochondrial Proteins / Q000235:genetics / Q000378:metabolism; D009765:Obesity / Q000209:etiology* / Q000235:genetics / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D012333:RNA, Messenger / Q000378:metabolism; D012119:Respiration / Q000187:drug effects; D022722:Thermogenesis / Q000187:drug effects*; D000071256:Uncoupling Protein 1
chemical_list: D004041:Dietary Fats; D005938:Glucocorticoids; D007473:Ion Channels; D024101:Mitochondrial Proteins; D012333:RNA, Messenger; C000604372:Ucp1 protein, mouse; D000071256:Uncoupling Protein 1; D003907:Dexamethasone